Balyasny Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.76M | Sell |
19,774
-4,753
| -19% | -$666K | ﹤0.01% | 1639 |
|
|
2025
Q4 | $3.01M | Buy |
24,527
+18,723
| +323% | +$2.28M | ﹤0.01% | 1665 |
|
|
2025
Q3 | $644K | Sell |
5,804
-351,444
| -98% | -$39.9M | ﹤0.01% | 2287 |
|
|
2025
Q2 | $39.6M | Sell |
357,248
-271,321
| -43% | -$28.9M | 0.06% | 415 |
|
|
2025
Q1 | $70.4M | Buy |
628,569
+192,286
| +44% | +$19.8M | 0.12% | 204 |
|
|
2024
Q4 | $40.3M | Buy |
436,283
+83,170
| +24% | +$7.49M | 0.06% | 391 |
|
|
2024
Q3 | $29.6M | Buy |
353,113
+204,320
| +137% | +$15.6M | 0.05% | 488 |
|
|
2024
Q2 | $10.2M | Buy |
148,793
+33,684
| +29% | +$2.25M | 0.02% | 876 |
|
|
2024
Q1 | $8.43M | Buy |
115,109
+88,468
| +332% | +$6.8M | 0.01% | 1005 |
|
|
2023
Q4 | $2.16M | Buy |
26,641
+15,213
| +133% | +$1.18M | ﹤0.01% | 1424 |
|
|
2023
Q3 | $856K | Buy |
+11,428
| New | +$879K | ﹤0.01% | 1603 |
|
|
2023
Q2 | – | Sell |
-369,463
| Closed | -$29.5M | – | 2464 |
|
|
2023
Q1 | $30.7M | Sell |
369,463
-53,303
| -13% | -$4.41M | 0.08% | 371 |
|
|
2022
Q4 | $36.3M | Sell |
422,766
-292,753
| -41% | -$23.2M | 0.1% | 261 |
|
|
2022
Q3 | $44.1M | Buy |
715,519
+2,779
| +0.4% | +$175K | 0.14% | 178 |
|
|
2022
Q2 | $44.1M | Sell |
712,740
-126,258
| -15% | -$7.82M | 0.14% | 181 |
|
|
2022
Q1 | $49.9M | Buy |
+838,998
| New | +$53.6M | 0.16% | 146 |
|
|
2021
Q2 | – | Sell |
-360,488
| Closed | -$24.1M | – | 2099 |
|
|
2021
Q1 | $23.3M | Buy |
360,488
+129,886
| +56% | +$8.38M | 0.11% | 234 |
|
|
2020
Q4 | $13.4M | Sell |
230,602
-18,449
| -7% | -$1.11M | 0.07% | 362 |
|
|
2020
Q3 | $15.7M | Buy |
+249,051
| New | +$17.3M | 0.12% | 260 |
|
|
2019
Q3 | – | Sell |
-34,762
| Closed | -$2.35M | – | 1326 |
|
|
2019
Q2 | $2.35M | Sell |
34,762
-253,782
| -88% | -$16.7M | 0.02% | 831 |
|
|
2019
Q1 | $18.8M | Buy |
288,544
+16,467
| +6% | +$1.09M | 0.12% | 238 |
|
|
2018
Q4 | $17M | Buy |
+272,077
| New | +$19M | 0.12% | 239 |
|
|
2018
Q3 | – | Sell |
-349,373
| Closed | -$24.8M | – | 1802 |
|
|
2018
Q2 | $24.8M | Sell |
349,373
-193,407
| -36% | -$13.7M | 0.11% | 259 |
|
|
2018
Q1 | $40.9M | Buy |
542,780
+378,243
| +230% | +$30.1M | 0.17% | 162 |
|
|
2017
Q4 | $11.8M | Sell |
164,537
-9,956
| -6% | -$756K | 0.04% | 580 |
|
|
2017
Q3 | $14.1M | Sell |
174,493
-346,635
| -67% | -$26.5M | 0.06% | 402 |
|
|
2017
Q2 | $36.9M | Buy |
521,128
+288,809
| +124% | +$19.2M | 0.15% | 178 |
|
|
2017
Q1 | $15.8M | Buy |
232,319
+212,503
| +1,072% | +$14.9M | 0.07% | 346 |
|
|
2016
Q4 | $1.42M | Buy |
19,816
+15,034
| +314% | +$1.12M | 0.01% | 941 |
|
|
2016
Q3 | $378K | Sell |
4,782
-55,235
| -92% | -$4.49M | ﹤0.01% | 783 |
|
|
2016
Q2 | $5.01M | Sell |
60,017
-267,426
| -82% | -$23.7M | 0.03% | 509 |
|
|
2016
Q1 | $30.1M | Buy |
327,443
+321,256
| +5,192% | +$29M | 0.18% | 172 |
|
|
2015
Q4 | $626K | Sell |
6,187
-161,348
| -96% | -$16.8M | ﹤0.01% | 785 |
|
|
2015
Q3 | $16.4M | Buy |
+167,535
| New | +$18.6M | 0.12% | 231 |
|
|
2015
Q2 | – | Sell |
-1,031,526
| Closed | -$113M | – | 1212 |
|
|
2015
Q1 | $101M | Buy |
+1,031,526
| New | +$105M | 0.82% | 11 |
|
Other funds holding GILD
VCM
VPM
Balyasny Asset Management's GILD Position: Q1 2026 in Review
Balyasny Asset Management reduced its Gilead Sciences (GILD) stake by 19% in Q1 2026, selling an estimated $666K and leaving 19,774 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1639.
Balyasny Asset Management first reported a position in GILD in Q1 2015 and has held it in 35 quarters since. The position peaked at $101M in Q1 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Balyasny Asset Management held 19,774 shares of Gilead Sciences worth $2.76M as of Q1 2026.
- Balyasny Asset Management sold 4,753 Gilead Sciences shares in Q1 2026, an estimated $666K.
- Gilead Sciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1639 holding.
- Balyasny Asset Management first reported a position in Gilead Sciences in Q1 2015 and has held it in 35 quarters since.
- Balyasny Asset Management's Gilead Sciences position peaked at $101M in Q1 2015.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.